Table 1.
V3 amino acid alterations associated with C-HIV coreceptor usage
|
Mutation a |
Phenotype |
Fisher’s exact test (p value) |
Mutation |
Phenotype |
Fisher’s exact test (p value) |
||
|---|---|---|---|---|---|---|---|
| CCR5 usage | CXCR4 usage | CCR5 usage | CXCR4 usage | ||||
| Asn6Tyr |
0 |
4.3 |
ns |
Gln18Arg |
1.1 |
20.3 |
<0.0001 |
| Asn7Lys |
0 |
4.3 |
ns |
Gln18His |
0.4 |
13 |
0.0002 |
| Thr8Ile |
0.2 |
7.2 |
0.014 |
Gln18Lys |
0 |
2.9 |
ns |
| Arg9Ile |
0 |
5.8 |
0.0289 |
Phe20Val |
0 |
7.2 |
0.0068 |
| Lys10Glu |
4.4 |
0 |
ns |
Phe20Trp |
0 |
2.9 |
ns |
| Ser11Arg |
0.2 |
15.9 |
<0.0001 |
Thr23- |
2.3 |
0 |
ns |
| Ser11Asn |
0 |
4.3 |
ns |
Thr23Arg |
0 |
5.8 |
0.0289 |
| Ser11His |
0 |
2.9 |
ns |
Gly24Lys |
1.3 |
13 |
0.0013 |
| Ser11Ile |
0 |
2.9 |
ns |
Asp25Arg |
0.2 |
10.1 |
0.0015 |
| Ser11Lys |
0 |
1.4 |
ns |
Asp25Lys |
0.6 |
17.4 |
<0.0001 |
| Ile12Lys |
0 |
2.9 |
ns |
Asp25Thr |
0 |
7.2 |
0.0068 |
| Arg13Asn |
0 |
2.9 |
ns |
Asp25His |
0 |
1.4 |
ns |
| Arg13- |
0.4 |
8.7 |
0.0067 |
Asp25- |
2.5 |
4.3 |
ns |
| Ile14Leu |
0.6 |
10.1 |
0.0015 |
Ile27Arg |
0 |
7.2 |
0.0068 |
| Ile14Thr |
0 |
4.3 |
ns |
Ile27Asn |
0 |
2.9 |
ns |
| 13-14 insertion |
0 |
40.4 |
<0.0001 |
Gly28Lys |
0 |
2.9 |
ns |
| Pro16Arg |
0 |
37.7 |
<0.0001 |
Ile30Val |
0 |
4.3 |
ns |
| Pro16Gln |
0 |
4.3 |
ns |
Gln32Glu |
8 |
0 |
0.0068 |
| Gly17Arg | 0.4 | 8.7 | 0.0067 | His34Phe | 0 | 7.2 | 0.0068 |
a Amino acid numbering is based on the consensus C-HIV V3 sequence.
Values are percentages of R5 or CXCR4-using C-HIV V3 sequences.
For these analyses, 69 unique CXCR4-using and 473 unique R5 C-HIV V3 sequences were included.
ns, not significant; -, deleted sequence.